Precision Medicine Software Market Report 2025

The precision medicine software market size has grown rapidly in recent years. It will grow from $2.12 billion in 2024 to $2.45 billion in 2025 at a compound annual growth rate (CAGR) of 15.4%. The growth in the historic period can be attributed to the increasing adoption of electronic health records (EHRs), expansion of genomic sequencing initiatives, rising investments in biotechnology and personalized medicine, growth in cancer genomics and targeted therapy research, and strengthening collaboration between the healthcare and technology sectors.

The precision medicine software market size is expected to see rapid growth in the next few years. It will grow to $4.29 billion in 2029 at a compound annual growth rate (CAGR) of 15%. The growth in the forecast period can be attributed to the rising demand for personalized treatment strategies, increasing focus on rare diseases and orphan drug development, growth in direct-to-consumer genetic testing, and enhanced regulatory support along with efforts toward data standardization. Major trends in the forecast period include the expansion of multi-omics data integration, a shift toward cloud-native platforms, emphasis on real-time clinical decision support, advancement of federated and privacy-preserving data models, and the adoption of digital twins for personalized treatment planning.

The increasing demand for personalized treatment is driving growth in the precision medicine software market. Personalized treatment involves tailoring medical care to an individual’s genetic makeup, lifestyle, and health history to achieve more effective outcomes. Advances in genomic technologies have accelerated this demand by enabling precise identification of genetic variations and supporting targeted therapies. Precision medicine software facilitates personalized care by analyzing genetic, clinical, and lifestyle data, improving diagnostic accuracy and treatment efficacy. For instance, in February 2024, the Personalized Medicine Coalition (PMC) reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, more than double the 12 approved in 2022, highlighting the growing adoption of genomically informed therapies.

Key players are developing advanced AI-driven platforms to streamline digital healthcare and reduce development costs. Digital healthcare uses technology to manage, deliver, and optimize health services. In July 2024, Huma Therapeutics Ltd, a UK-based digital health company, launched its Cloud Platform, enabling rapid, no-code creation and deployment of regulated health applications powered by AI. The platform includes ready-made components, device connectivity, and compliance with regulatory standards (FDA Class II, EU MDR IIb, Saudi FDA C), helping organizations of all sizes deliver cost-efficient, AI-driven care and accelerate digital health innovation.

In January 2023, QuartzBio, part of Precision for Medicine, acquired SolveBio Inc. to strengthen its SaaS platform. This integration enhances enterprise-level data management capabilities, enabling streamlined handling of clinical samples and biomarker data throughout the drug development lifecycle. SolveBio specializes in genomic and clinical data integration and analysis, supporting more precise, data-driven decision-making in precision medicine.

Major players in the precision medicine software market are Koninklijke Philips N.V., Palantir Technologies Inc., Tempus Labs Inc., Myriad Genetics Inc., Foundation Medicine Inc., Guardant Health Inc., Color Genomics Inc., NantHealth Inc., SOPHiA GENETICS SA, Aignostics GmbH, MVision AI Oy, Fabric Genomics Inc., QUIBIM S.L., Syapse Inc., PierianDx Inc., 2bPrecise LLC, SimBioSys Inc., Navignostics AG, xCures Inc., LifeOmic Holdings LLC.

North America was the largest region in the precision medicine software market in 2024. The regions covered in precision medicine software market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the precision medicine software market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Precision medicine software refers to specialized digital platforms that analyze individual patient data - including genetic, molecular, clinical, and lifestyle information - to create personalized treatment and prevention strategies. Its main purpose is to assist clinicians in making data-driven decisions that optimize therapeutic outcomes based on each patient’s unique biological profile.

The primary types of precision medicine software include clinical decision support systems (CDSS), genomic data analysis tools, data integration and management software, patient management software, and bioinformatics tools. Clinical decision support systems are health IT solutions designed to help healthcare professionals make informed clinical decisions by providing evidence-based knowledge, patient-specific data, and treatment recommendations at the point of care. These systems utilize technologies such as artificial intelligence and machine learning, big data analytics, blockchain, the Internet of Medical Things (IoMT), and CRISPR/gene-editing tools, and are deployed via cloud-based or on-premise infrastructures. They are applied across areas such as oncology, central nervous system disorders, immunology, cardiovascular diseases, and more, serving end users including healthcare providers, research institutions, government organizations, pharmaceutical companies, and biotechnology firms.

The precision medicine software market research report is one of a series of new reports that provides precision medicine software market statistics, including the precision medicine software industry global market size, regional shares, competitors with the precision medicine software market share, detailed precision medicine software market segments, market trends, and opportunities, and any further data you may need to thrive in the precision medicine software industry. This precision medicine software market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The precision medicine software market consists of revenues earned by entities by providing services such as biomarker identification, patient stratification, treatment planning, data integration from electronic health records (EHRs), and laboratory information systems. The market value includes the value of related goods sold by the service provider or included within the service offering. The precision medicine software market also consists of sales of clinical analytics platforms, genomic interpretation tools, bioinformatics software, and AI-driven diagnostic solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.